Compounded Tirzepatide Latest Research: New Indications, Trials & What’s Coming

Introduction

Tirzepatide’s clinical footprint has expanded rapidly. FDA-approved indications now include type 2 diabetes (Mounjaro®, 2022), chronic weight management (Zepbound®, 2023), and moderate-to-severe obstructive sleep apnea in obesity (Zepbound, December 2024). Active phase 3 programs cover MASH, heart failure with preserved ejection fraction, cardiovascular outcomes (SURPASS-CVOT), chronic kidney disease, and adolescent obesity.

SURMOUNT-OSA (Malhotra 2024 NEJM) showed 25.3 event/hour reduction in apnea-hypopnea index, the first medication ever approved for OSA. SUMMIT (Packer 2024 NEJM) demonstrated symptomatic and clinical benefit in HFpEF. SYNERGY-NASH (phase 2) showed strong signals for fatty liver resolution, supporting the active phase 3 program.

This article reviews the published trial evidence for each new and emerging indication, the pipeline, and what compounded tirzepatide users should know.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Did SURMOUNT-OSA Show?

SURMOUNT-OSA tested tirzepatide 10-15 mg weekly in 469 adults with moderate-to-severe obstructive sleep apnea (apnea-hypopnea index 15-90/hour) and obesity. Two trials ran in parallel: one in patients not using CPAP and one in patients on stable CPAP therapy.

Quick Answer: SURMOUNT-OSA: 25.3 events/hour AHI reduction; FDA approval December 2024 (Malhotra 2024 NEJM)

Primary endpoint was change in AHI at 52 weeks. Tirzepatide reduced AHI by 25.3 events/hour vs 5.3 on placebo in the non-CPAP cohort, and by 29.3 vs 5.5 in the CPAP cohort. About 50% of tirzepatide patients reached AHI <5 (clinically considered cured) at 52 weeks. Quality of life, daytime sleepiness, and cardiovascular biomarkers all improved.

Malhotra et al. published in NEJM June 2024. The FDA approved Zepbound for moderate-to-severe OSA in obese adults in December 2024. This was the first medication ever approved for OSA, opening a treatment option for patients who can’t tolerate CPAP.

What Does SUMMIT Mean for Heart Failure?

SUMMIT tested tirzepatide 10-15 mg weekly in 731 adults with heart failure with preserved ejection fraction (HFpEF) and BMI ≥30. Primary composite endpoint was time to worsening heart failure event or cardiovascular death over a median 104 weeks.

Tirzepatide reduced the composite by 38% vs placebo (hazard ratio 0.62, 95% CI 0.41-0.95, p=0.026). KCCQ clinical summary score improved 19.5 points more than placebo. Six-minute walk distance improved 18.3 meters more. NT-proBNP and CRP both dropped.

Packer et al. published in NEJM November 2024. The findings establish tirzepatide as a meaningful therapy for obesity-associated HFpEF. The combined data from SURMOUNT-OSA, SUMMIT, and earlier trials support tirzepatide’s role beyond diabetes and basic weight loss into specific cardiometabolic indications.

What’s the MASH Story?

SYNERGY-NASH (Loomba 2024 NEJM) is the phase 2 trial of tirzepatide in MASH (formerly NASH) with biopsy-confirmed stage 2-3 fibrosis. The 190-participant trial tested 5, 10, and 15 mg weekly vs placebo for 52 weeks.

MASH resolution without worsening of fibrosis occurred in 44% (5 mg), 56% (10 mg), and 62% (15 mg) vs 10% on placebo (p<0.001 for all doses). At least 1-stage fibrosis improvement without MASH worsening occurred in 51-55% of tirzepatide patients vs 30% on placebo, though the difference didn't reach statistical significance at all doses.

Phase 3 trials are ongoing. If positive, tirzepatide could become a first-line MASH therapy alongside semaglutide (pending ESSENCE approval) and resmetirom (Rezdiffra®, approved March 2024).

What About Cardiovascular Outcomes?

SURPASS-CVOT is the cardiovascular outcomes trial enrolling approximately 13,000 adults with type 2 diabetes and elevated cardiovascular risk. The active-control design compares tirzepatide vs dulaglutide rather than placebo, which is unusual and provides a head-to-head comparison of two GLP-1-based therapies.

Topline results are expected in 2025. The primary endpoint is time to first major adverse cardiovascular event (cardiovascular death, nonfatal MI, or nonfatal stroke). Secondary endpoints include hospitalizations for heart failure, kidney outcomes, and all-cause mortality.

If positive, SURPASS-CVOT will establish tirzepatide as cardioprotective and likely lead to a cardiovascular indication expansion. The active-control design also has implications for how the field considers GIP/GLP-1 dual agonism vs GLP-1 alone.

What’s Happening with Kidney Disease Research?

Tirzepatide doesn’t have a dedicated CKD trial of FLOW’s size, but exploratory analyses from SURPASS-4 suggested beneficial effects on albuminuria and eGFR decline rate. A dedicated CKD trial (SURPASS-CKD) is in early planning.

Existing data suggest tirzepatide produces kidney effects similar in pattern to semaglutide, though direct comparison data are limited. For patients with diabetes and CKD, both GLP-1 and tirzepatide are reasonable choices based on the evidence available.

For non-diabetic CKD, the data are sparse for both molecules. Dedicated trials are needed before strong recommendations can be made.

What About Adolescent Obesity?

SURMOUNT-Adolescents is the phase 3 trial of tirzepatide in adolescents ages 12-17 with obesity. Topline results expected 2025-2026. The trial follows the design of STEP TEENS (semaglutide in adolescents) which showed 16.1% weight loss at 68 weeks.

Adolescent obesity is increasingly recognized as needing pharmacological intervention alongside lifestyle therapy, particularly given the trajectory of metabolic complications. If SURMOUNT-Adolescents is positive, tirzepatide will likely receive a pediatric weight management indication.

Compounded tirzepatide should not be used in adolescents outside of specialized programs. Telehealth platforms like TrimRx restrict prescribing to adults 18 and older.

What’s the PCOS Evidence?

Polycystic ovary syndrome is closely linked to insulin resistance and obesity. Tirzepatide trials in PCOS are limited compared to semaglutide, but observational and small clinical studies suggest:

• Improved menstrual regularity in 60-75% of patients within 6 months
• Reduced testosterone and improved hirsutism scores
• Likely improved ovulation and fertility, though dedicated trials are needed
• Substantial weight loss in PCOS patients similar to non-PCOS obesity

A 2024 trial in Reproductive Biomedicine Online showed tirzepatide 10 mg produced 18.4% weight loss in PCOS patients at 48 weeks. Tirzepatide is increasingly prescribed off-label for PCOS by reproductive endocrinologists and obesity specialists. The TrimRx free assessment quiz captures PCOS as a qualifying comorbidity for weight management therapy.

What About Knee Osteoarthritis and Joint Pain?

Tirzepatide trials in knee OA are smaller than the STEP 9 program for semaglutide. Observational data suggest pain improvement tracks closely with weight loss in patients with obesity-related knee OA, often exceeding what weight loss alone would predict.

The IDEA trial (Messier 2013 JAMA) established that 10% weight loss produces about 50% pain reduction in obesity-related knee OA. Tirzepatide produces 15-20% weight loss on average, suggesting substantial pain benefit in this population.

Dedicated tirzepatide knee OA trials are being planned. The mechanism likely combines mechanical unloading from weight loss with direct anti-inflammatory effects from GLP-1 and GIP receptor activation.

Key Takeaway: SYNERGY-NASH phase 2: 44-62% MASH resolution at 52 weeks (Loomba 2024 NEJM)

What About Cancer Prevention?

Multiple observational studies suggest GLP-1 therapy (including tirzepatide) reduces risk of obesity-associated cancers. A 2024 JAMA Network Open cohort analysis of 1.65 million people with type 2 diabetes showed GLP-1 therapy associated with 15-44% lower incidence across 10 obesity-related cancers vs insulin.

Tirzepatide data alone are smaller but consistent with the GLP-1 class signal. Randomized confirmation is needed before clinical recommendations change. The cardiovascular and OSA trials have shown remarkably consistent class effects, and the cancer signal may prove similarly strong over time.

The thyroid cancer concern from rodent data remains unresolved but human data after 10+ years of GLP-1 use don’t show an elevated thyroid cancer signal at population level.

What New GLP-1 Drugs Are Coming?

Several next-generation incretin agonists are in development:

Retatrutide (Eli Lilly) is a triagonist hitting GLP-1, GIP, and glucagon receptors. Jastreboff 2023 NEJM phase 2 data showed 24.2% weight loss at 48 weeks on 12 mg weekly, the highest weight loss yet seen with any obesity drug. Phase 3 program is ongoing.

CagriSema (Novo Nordisk) combines cagrilintide (amylin analog) with semaglutide. REDEFINE phase 3 trials are testing this combination with topline results expected 2025-2026.

Orforglipron (Eli Lilly) is an oral non-peptide GLP-1 agonist that doesn’t need refrigeration or injection. Phase 3 trials including weight loss and diabetes are ongoing with results expected 2025.

Survodutide (Boehringer Ingelheim) is a glucagon/GLP-1 dual agonist with phase 2 data showing strong MASH and weight loss effects.

What Does All This Mean for Compounded Tirzepatide Users?

The drug’s clinical value continues to expand. People taking compounded tirzepatide for weight loss are likely also getting cardiovascular, metabolic, sleep apnea, and possibly cognitive benefits.

The breadth of evidence supports long-term use rather than short courses. Most clinical evidence now favors continued therapy for metabolic and cardiovascular protection.

TrimRx personalizes treatment plans around your specific health goals and conditions. The free assessment quiz captures cardiovascular history, sleep apnea status, kidney function, and other factors that influence long-term planning.

How Is the Regulatory Landscape Changing for GLP-1 and Dual Agonist Drugs?

The FDA has expanded GLP-1 and dual agonist indications faster than any other drug class in recent memory. Within 2 years (early 2023 to early 2025), tirzepatide gained obesity and OSA indications. SURPASS-CVOT results expected in 2025 may add a cardiovascular indication.

Medicare expansion remains a key policy question. The OSA indication added in December 2024 opened limited Medicare access. Broader anti-obesity coverage requires statutory change. Bipartisan legislation has been introduced repeatedly but not passed.

State Medicaid coverage is expanding patchily. Coverage decisions are increasingly based on cost-effectiveness modeling that includes long-term cardiovascular, metabolic, and sleep apnea outcomes.

What About Cost Trajectories?

Brand tirzepatide list prices have held relatively flat in the US since launch despite high demand. Eli Lilly’s LillyDirect cash pay program in 2024 introduced the first major price break, offering Zepbound vials at 30-50% below pen retail.

International pricing differs dramatically. Brand tirzepatide in Canada, Germany, and the UK retails for 20-40% of US prices. Patent and manufacturing exclusivity remain in place for tirzepatide through the late 2030s in most markets.

Generic competition for tirzepatide is not expected before 2036 in the US. Until then, brand prices, manufacturer cash-pay programs, and legally compounded preparations are the main supply pathways.

What’s the State of Tirzepatide Research in Non-obesity Conditions?

Beyond the indications discussed earlier, tirzepatide is being studied in:

• Heart failure with reduced EF (HFrEF): less established than HFpEF data
• Parkinson’s disease: very early phase 2 work
• Inflammatory bowel disease: possible anti-inflammatory effects
• Bone health: some signals suggest neutral to positive bone effects
• Polycystic kidney disease: early-stage investigation

Most of these are early-stage studies, not phase 3 programs. The breadth reflects how widely GIP and GLP-1 receptors are expressed across body systems.

What Does the Next Decade Likely Look Like for Tirzepatide Users?

Several reasonable predictions:

Indications will continue to expand. MASH approval is likely within 2-3 years. SURPASS-CVOT results may add a cardiovascular indication in 2025-2026. Adolescent obesity approval is also pending.

Costs will likely drop. LillyDirect set a precedent for direct cash pricing. Compounding will continue under section 503A pending clinical justification.

New molecules will compete. Retatrutide (triagonist), CagriSema, orforglipron, and survodutide may shift the standard of care. Patients on tirzepatide today may switch to newer agents over the next 5 years if those agents prove better.

The long-term safety record continues to strengthen. After several years of tirzepatide use at population scale, no new major safety signals have emerged. Long-term effects on cognition, cancer risk, and overall mortality appear net positive.

Bottom line: Retatrutide phase 2: 24.2% weight loss at 48 weeks; phase 3 ongoing

FAQ

Will Compounded Tirzepatide Be Approved for These New Indications?

No. Compounded medications are not FDA-approved for any specific indication. The brand drugs (Mounjaro, Zepbound) receive new indications based on trials. Compounded preparations contain the same active ingredient and produce the same biological effects, but they aren’t separately approved.

Should I Take Tirzepatide for OSA If I Have It?

If you have moderate-to-severe OSA and obesity, tirzepatide is now an FDA-approved option. CPAP remains a primary therapy but can be combined with or replaced by tirzepatide in patients who don’t tolerate CPAP. Discuss with your sleep medicine provider.

When Will MASH Approval Come for Tirzepatide?

Phase 3 MASH trials are ongoing with results expected in 2026-2027. If positive, FDA approval would follow. Resmetirom is currently the only approved MASH drug; semaglutide may be approved before tirzepatide based on ESSENCE filing.

Is Tirzepatide Proven Better Than Semaglutide for Cardiovascular Disease?

Not yet. SURPASS-CVOT (active-control vs dulaglutide) results expected 2025. SELECT showed semaglutide reduces cardiovascular events by 20%. Direct head-to-head cardiovascular data for tirzepatide vs semaglutide doesn’t yet exist.

Should I Use Tirzepatide to Quit Drinking?

Off-label use for alcohol use disorder is not recommended outside trials. Early-stage tirzepatide studies in addiction are ongoing. Standard evidence-based therapies (naltrexone, acamprosate, behavioral therapy) remain first-line.

Can Compounded Tirzepatide Be Prescribed for OSA?

Compounded tirzepatide contains the same active ingredient and produces the same biological effects shown in SURMOUNT-OSA. However, compounded medications are prescribed under individual provider discretion, not for specific approved indications. Discuss with a sleep specialist.

What’s the Most Exciting Next-generation Drug?

Retatrutide stands out, with 24.2% weight loss in phase 2 vs tirzepatide’s 20.9% in SURMOUNT-1. If phase 3 confirms the result, retatrutide could become the new gold standard for weight loss medication around 2027-2028.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Related Articles

• Mazdutide Latest Research: New Indications, Trials & What’s Coming
• Tirzepatide Latest Research: New Indications, Trials & What’s Coming
• Exenatide Latest Research: New Indications, Trials and Whats Coming
• Pemvidutide Latest Research: New Indications, Trials & What’s Coming